Research Feed
HRMY: A Fairly Priced Patent Binary
Harmony Biosciences ($27.50, $1.6B market cap) is down 25% in a week. Two things happened simultaneously: Q4 EPS missed by 46.5% ($0.57 vs $1.07), and the bench trial for the last remaining ANDA patent challenger (AET Pharma) concluded February 17-19. Market is pricing this as a death sentence. It i